<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>332</serviceExecutionTime><Drug id="96946"><DrugName>ART-648</DrugName><DrugSynonyms><Name><Value>TAK-648</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ART-648</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20300">Takeda Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1174524">ARTham Therapeutics Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="20300">Takeda Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1174524" type="Company"><TargetEntity id="5066601053" type="organizationId">ARTham Therapeutics KK</TargetEntity></SourceEntity><SourceEntity id="20300" type="Company"><TargetEntity id="4295877353" type="organizationId">Takeda Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="100" type="ciIndication"><TargetEntity id="10061835" type="MEDDRA"></TargetEntity><TargetEntity id="D003928" type="MeSH"></TargetEntity><TargetEntity id="-271673667" type="omicsDisease"></TargetEntity><TargetEntity id="342" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2637" type="ciIndication"><TargetEntity id="K75.81" type="ICD10"></TargetEntity><TargetEntity id="1412" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="304" type="Action"><TargetEntity id="470" type="Mechanism">Phosphodiesterase PDE4 Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="100">Diabetic nephropathy</Indication><Indication id="2637">Non-alcoholic steatohepatitis</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsPrimary><ActionsPrimary><Action id="304">PDE 4 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="399">Hypoglycemic agent</Action><Action id="664">Fibrosuppressant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-06-20T11:55:28.000Z</LastModificationDate><ChangeDateLast>2019-05-21T00:00:00.000Z</ChangeDateLast><AddedDate>2015-05-20T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1174524" linkType="Company"&gt;ARTham Therapeutics&lt;/ulink&gt; (presumably under license from &lt;ulink linkID="20300" linkType="Company"&gt;Takeda&lt;/ulink&gt;) is developing ART-648 (TAK-648), a phosphodiesterase type 4 inhibitor, for the potential oral treatment of  type  2 diabetes mellitus (T2DM) and diabetic nephropathy [&lt;ulink linkID="2058917" linkType="Reference"&gt;2058917&lt;/ulink&gt;], [&lt;ulink linkID="2092631" linkType="Reference"&gt;2092631&lt;/ulink&gt;],  [&lt;ulink linkID="1659022" linkType="Reference"&gt;1659022&lt;/ulink&gt;]. The company is also investigating ART-648 for the potential treatment of non-alcoholic steatohepatitis. In April 2019, in vivo data were presented [&lt;ulink linkID="2142008" linkType="Reference"&gt;2142008&lt;/ulink&gt;]. In December 2018, a phase I study in healthy Japanese volunteers was initiated [&lt;ulink linkID="2092631" linkType="Reference"&gt;2092631&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Takeda was developing TAK-648, for the potential oral treatment of  T2DM and diabetic nephropathy [&lt;ulink linkID="1659022" linkType="Reference"&gt;1659022&lt;/ulink&gt;], [&lt;ulink linkID="1659045" linkType="Reference"&gt;1659045&lt;/ulink&gt;], [&lt;ulink linkID="1707903" linkType="Reference"&gt;1707903&lt;/ulink&gt;].  In  May 2015, a phase I trial was initiated  [&lt;ulink linkID="1659022" linkType="Reference"&gt;1659022&lt;/ulink&gt;], [&lt;ulink linkID="1659045" linkType="Reference"&gt;1659045&lt;/ulink&gt;]. However, in May 2016, development was discontinued based on strategic portfolio decision [&lt;ulink linkID="1760957" linkType="Reference"&gt;1760957&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September 2018, &lt;ulink linkID="1062532" linkType="Company"&gt;Oita University&lt;/ulink&gt; Faculty of Medicine-led randomized, double-blind, parallel assigned, phase I study (&lt;ulink linkID="358761" linkType="Protocol"&gt;UMIN000034454&lt;/ulink&gt;, R000039287) was to begin in Japan in December 2018, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses of ART-648 in healthy Japanese subjects (expected n = 32), in collaboration with ARTham  [&lt;ulink linkID="2092631" linkType="Reference"&gt;2092631&lt;/ulink&gt;]. In December 2018, the trial was initiated [&lt;ulink linkID="2092631" linkType="Reference"&gt;2092631&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, clinical data from randomized, placebo-controlled, single-rising dose (SRD) and multiple rising-dose (MRD) studies in in healthy Japanese and non-Japanese subjects and subjects with T2DM  were presented at the 2016 Annual Meeting of the ACCP in Bethesda, MD. Following single or multiple doses from 0.05 to 0.85 mg, TAK-648 was rapidly absorbed with median Tmax values in the range of 0.5 to1.5 h in healthy Japanese and non-Japanese or T2DM subjects. Cmax and AUC increased nearly proportionately with increasing dose across the dose range (0.05 to 0.85 mg) with   &amp;lt; 30% accumulation following multiple dosing. Mean t1/2 of TAK-648 was ranged from 6.01 to 16.5 h and generally found to increase with increasing dose.  No gastrointestinal tolerability, neurological or psychiatric effect, hypoglycemia or any other safety concerns were reported [&lt;ulink linkID="1894951" linkType="Reference"&gt;1894951&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, a randomized, double-blind, placebo-controlled, multiple-dose,Â phase I trial (&lt;ulink linkID="228815" linkType="Protocol"&gt;NCT02430870&lt;/ulink&gt;; TAK-648-1002) was initiated in the US, in patients (expected n = 40) with T2DM, to assess the safety and efficacy of TAK-648. At that time, the trial was expected to complete in July 2015. In October 2015, the trial was completed [&lt;ulink linkID="1659022" linkType="Reference"&gt;1659022&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2019, in vivo data were presented at the 2019 EASL International Liver Congress in Vienna, Austria. In dyslipidemic LDL receptor null mice fed with modified choline-deficient diet, po ART-648  as prophylactic (1, 3, and 10 mg/kg for 7 weeks) or therapeutic modes (4 and 8 mg/kg for 10 weeks) dose-dependently decreased hepatic fibrosis area (p &amp;lt; 0.05), triglyceride content (p &amp;lt; 0.05) and gene expression of collagen-I (p &amp;lt; 0.05), TNF-alpha (p &amp;lt; 0.05), and TIMP-1 (p &amp;lt; 0.05). In diet-induced obese mice, ART-648 (1 and 3 mg/kg) significantly decreased body weight (p &amp;lt; 0.025), food intake (p &amp;lt; 0.025) and fat mass (p &amp;lt; 0.025) [&lt;ulink linkID="2142008" linkType="Reference"&gt;2142008&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1174524">ARTham Therapeutics Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2637">Non-alcoholic steatohepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-04-13T00:00:00.000Z</StatusDate><Source id="2142008" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1174524">ARTham Therapeutics Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-03T00:00:00.000Z</StatusDate><Source id="2092631" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1174524">ARTham Therapeutics Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-03T00:00:00.000Z</StatusDate><Source id="2092631" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-11T00:00:00.000Z</StatusDate><Source id="1760957" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-11T00:00:00.000Z</StatusDate><Source id="1760957" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-08T00:00:00.000Z</StatusDate><Source id="1659045" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-07T00:00:00.000Z</StatusDate><Source id="1659022" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-30T00:00:00.000Z</StatusDate><Source id="1707903" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1174524">ARTham Therapeutics Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-14T00:00:00.000Z</StatusDate><Source id="2092631" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1174524">ARTham Therapeutics Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-14T00:00:00.000Z</StatusDate><Source id="2092631" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01522"><Name>PDE 4</Name><SwissprotNumbers><Swissprot>Q22000</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2977772" number="WO-2015110394" title="Treatment of partly controlled or uncontrolled severe asthma with a PDE4 inhibitor (and in combination with a leukotriene modifier)"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>